Top Markets
#1 MON MON +2,760.08%
#2 $1 is all you need $1 is all you need +1,328.53%
#3 PYTHIA PYTHIA +52.36%
#4 eCash eCash +37.30%
#5 PinGo PinGo +24.63%
#6 Siren Siren +24.18%
#7 Collector Crypt Collector Crypt +23.96%
#8 SAFEcoin SAFEcoin +19.72%
#9 Janction Janction +19.66%
#10 Velvet Velvet +15.56%
Coin of the day
MON MON
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
Rangering i aksjer #13334
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Aksjekurs
$0.30840035
Markedsverdi
$94.37M
Endring (1 dag)
0.00%
Endring (1 år)
-34.60%
Land
FR
Handel Sensorion SA (ALSEN)

Kategori

Healthcare
Antall utestående aksjer for Sensorion SA (ALSEN)
Antall utestående aksjer per December 2025: 300.92M
Ifølge Sensorion SA sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 300.92M. Ved slutten av December 2023 hadde selskapet 133.42M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Sensorion SA (ALSEN) fra 2011 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
2026 (TTM) 300.92M 5.97%
2024 283.97M 112.83%
2023 133.42M 67.12%
2022 79.84M 0.18%
2021 79.69M 31.16%
2020 60.76M 225.81%
2019 18.65M 63.39%
2018 11.41M 58.34%
2017 7.21M 5.84%
2016 6.81M 59.47%
2015 4.27M 30.90%
2014 3.26M 0.00%
2013 3.26M 0.00%
2012 3.26M 0.00%
2011 3.26M 0.00%
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 4.44B 1,376.33%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 254.10M -15.56%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 104.00M -65.44%
US
UCB SA UCB SA
UCB SA
UCB.BR
 190.00M -36.86%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 61.42M -79.59%
NL